Table 2.
Comparison of parameters of clinical presentation, precipitating factors, cardiovascular risk factors and demographics between patients with and without preadmission betablocker use by Mann–Whitney-U test or, if nominal, by Chi Square test.
| TTS Patients with Betablocker Therapy (n = 19) |
TTS Patients without Betablocker Therapy (n = 37) |
p = | |||
|---|---|---|---|---|---|
| Median or n (%) | IQR | Median or n (%) | IQR | ||
| Age (years) | 76.0 | 64.0–78.0 | 67.0 | 61.0–78.0 | 0.068 |
| Sex (female) | 89.5 | 94.6 | 0.481 | ||
| BMI (kg/m2) | 26.7 | 21.7–29.3 | 23.9 | 21.8–29.7 | 0.528 |
| Smoking | 21.1 | 32.4 | 0.372 | ||
| Oncologic disease | 21.1 | 8.1 | 0.166 | ||
| History of AF | 26.3 | 2.7 | 0.007 | ||
| Hypertension | 84. 2 | 59.5 | 0.009 | ||
| History of stroke | 21.1 | 0.0 | 0.004 | ||
| Non-significant Coronary artery disease | 42.1 | 35.1 | 0.910 | ||
| EF (%) | 40.0 | 35.0–45.0 | 42.5 | 40.0–50.0 | 0.277 |
| SBP (mmHg) | 130.0 | 112.0–159.0 | 133.0 | 119.0–158.0 | 0.249 |
| DBP (mmHg) | 85.5 | 71.0–98.3 | 82.5 | 70.0–92.0 | 0.542 |
| Heart rate (bpm) | 79.0 | 72.8–90.0 | 76.0 | 63.5–89.5 | 0.396 |
| QTc (ms) | 471.0 | 442.5–519.3 | 455.0 | 432.0–480.0 | 0.215 |
| Creatinine (mg/dL) | 0.8 | 0.7–1.0 | 0.7 | 0.7–0.9 | 0.010 |
| LDL (mg/d) | 100.0 | 70.3–137.0 | 90.5 | 76.5–120.5 | 0.695 |
| CRP (mg/L) | 0.6 | 0.4–3.9 | 0.5 | 0.1–0.8 | 0.267 |
| HbA1c (%) | 5.9 | 5.5–5.9 | 5.4 | 5.1–5.5 | 0.003 |
| (hs)Troponin (pg/mL) | 178.0 | 51.0–837.0 | 198.0 | 61.0–422.5 | 0.828 |
| Pro-BNP (pg/mL) | 3789.5 | 729.9–5816.8 | 2709.0 | 459.7–4999.5 | 0.361 |
AF (Atrial Fibrillation), BMI (Body Mass Index), CRP (C Reactive Protein), DBP (Diastolic Blood Pressure), EF (Ejection fraction), HbA1c (hemoglobin A1c), SBP (Systolic Blood Pressure), LDL (low density lipoprotein).